Braidwell LP Biocryst Pharmaceuticals Inc Transaction History

Braidwell LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $11.4 Million - $17.9 Million	-2,338,900 Reduced 40.9%	3,379,577 $17.2 Billion
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $1.77 Million - $2.41 Million	355,497 Added 6.63%	5,718,477 $34.3 Billion
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $17.3 Million - $20.4 Million	2,571,100 Added 92.09%	5,362,980 $38 Billion
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $5.89 Million - $7.46 Million	846,746 Added 43.53%	2,791,880 $19.7 Billion
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $15.4 Million - $23 Million	1,945,134 New	1,945,134 $16.2 Billion

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

Stay updated on Braidwell LP with notifications on news.